Project Grant FF204K114027

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $115,000 to Navrogen Inc. to characterize HIO-2, a tumor-produced protein that inhibits therapeutic antibody-mediated cellular cytotoxicity. The goal is to generate and test compounds that can overcome the immunosuppression mediated by HIO-2, which has been found to block antibody binding to the CD16A Fc receptor, thereby inhibiting antibody-dependent cellular cytotoxicity (ADCC)...

This $149,000 Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), will fund research to understand the role of the transcription factor Basonuclin-1 (BNC-1) in the progression of triple-negative inflammatory breast cancer (IBC). The research aims to (1) investigate how BNC-1 promotes oncogenic phenotypes, leading to IBC progression and metastasis using 3D cell culture models, and (2)...

This Project Grant award of $303,274 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports Antiger Therapeutics Inc., a startup biotech company, in developing targeted immunotherapies for Type 1 Diabetes (T1D). The primary objective is to engineer Peptide-HLA-DQ8 complex biologics that can selectively block the pathogenic T cells responsible for the autoimmune response in T1D. This innovative...

This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) provides $661,072 to Northwestern University to develop a novel, first-in-class small molecule inhibitor that targets the USP22 oncogene. The goal is to create a therapy with dual immuno-activating and cancer-targeting efficacy to treat triple negative breast cancer. The research, conducted in partnership with startup company Exomira Medicine Inc., aims to advance the therapeutic...

This federal Cooperative Agreement award, with a total funding amount of $1,207,770.00 and an award date of January 1, 2025, was granted by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award will support research to investigate the role of genetically-controlled thymic epithelial cell (TEC) and hematopoietic stem cell (HSC) abnormalities in driving the development...

The National Cancer Institute (NCI) awarded a $825,857 Cooperative Agreement under the Cancer Cause and Prevention Research program (CFDA 93.393) to Health Research, Inc. at Roswell Park Comprehensive Cancer Center. The goal of this 5-year award is to catalyze collaboration across the Cancer Immunoprevention Network (CIP-NET) and manage, integrate, and disseminate the data and resources generated by the network. Key objectives include fostering a collaborative research community, providing...

The National Institutes of Health (NIH) Office of Research Infrastructure Programs (ORIP) awarded a $1,860,338 Cooperative Agreement to the University of California, Irvine (UCI) on August 15, 2025 under the Research Infrastructure Programs (CFDA 93.351). The goal of this project is to establish a Center for Modeling Non-Coding Disease Variants (NODIVA) that will leverage access to rare and undiagnosed disease consortia to test high-penetrance disease associations and develop targeted...

This $398,728 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports the development of a novel homologous recombination (HR) inhibitor, CP-8, to sensitize triple-negative breast cancer (TNBC) cells to DNA-damaging agents. The project aims to examine the synergy of CP-8 with various DNA-damaging therapies, including PARP inhibitors and ionizing radiation, in TNBC cell lines, patient-derived xenograft models, and in vivo...

This Cooperative Agreement award, in the amount of $816,325.00, was granted by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award will support a collaborative research project to optimize and evaluate novel small molecule "PAIR" inhibitors that target the unfolded protein response (UPR) pathway in pancreatic beta cells, with the goal of preventing and...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $306,500 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Qrono, Inc., a for-profit medical research and development company. The grant funding supports the development of QR402, a first-in-class, oral nanomedicine that uses an AMPK pathway agonist to target intestinal dendritic cells and restore immunological tolerance as a preventative therapy for type 1 diabetes. The goal is to...